DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,110.00
-270.00 (-5.02%)
At close: Mar 9, 2026
4.71%
Market Cap 138.19B
Revenue (ttm) 238.39B
Net Income (ttm) 770.31M
Shares Out 27.04M
EPS (ttm) 28.46
PE Ratio 179.53
Forward PE n/a
Dividend 120.00 (2.52%)
Ex-Dividend Date Dec 29, 2025
Volume 112,042
Average Volume 249,589
Open 5,330.00
Previous Close 5,380.00
Day's Range 5,040.00 - 5,330.00
52-Week Range 4,720.00 - 6,390.00
Beta 0.47
RSI 43.99
Earnings Date Mar 19, 2026

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip... [Read more]

Industry Pharmaceutical Preparations
Founded 1970
Employees 404
Stock Exchange KOSDAQ
Ticker Symbol 006620
Full Company Profile

Financial Performance

In 2024, DongKoo Bio & Pharma's revenue was 249.27 billion, an increase of 15.57% compared to the previous year's 215.69 billion. Earnings were 2.04 billion, a decrease of -82.77%.

Financial Statements

News

There is no news available yet.